Corrigendum: Impact of adjuvant: trivalent vaccine with quadrivalent-like protection against heterologous Yamagata-lineage influenza B virus.

导出 LinkOut

翻译打印收藏纠错

作者： Mallory L,Myers ^[1] ; John R,Gallagher ^[1] ; De'Marcus D,Woolfork ^[1] ; Regan K,Stradtmann-Carvalho ^[1] ; Samantha,Maldonado-Puga ^[1] ; Kevin W,Bock ^[2] ; Seyhan,Boyoglu-Barnum ^[3] ; Hubza,Syeda ^[3] ; Adrian,Creanga ^[3] ; Derron A,Alves ^[2] ; Masaru,Kanekiyo ^[3] ; Audray K,Harris ^[1]

作者单位： Structural Informatics Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States. ^[1] Infectious Disease Pathogenesis Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States. ^[2] Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States. ^[3]

关键词 MF59 adjuvant Yamagata lineage challenge commercial vaccine influenza B

DOI 10.3389/fimmu.2023.1283355

PMID 37771593

发布时间 2023-09-29

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Frontiers in immunology

2023年14卷

1283355页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Corrigendum: Impact of adjuvant: trivalent vaccine with quadrivalent-like protection against heterologous Yamagata-lineage influenza B virus.

Frontiers in immunology

相似文献

Frontiers in immunology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Corrigendum: Impact of adjuvant: trivalent vaccine with quadrivalent-like protection against heterologous Yamagata-lineage influenza B virus.

Frontiers in immunology

相似文献

Frontiers in immunology

相关期刊

检索历史清除